Gene Therapy

Our most ambitious goal is to develop a gene therapy that addresses the underlying cause of FARS2 deficiency, offering the possibility of slowing, stopping, or even reversing aspects of this devastating disease.

FARS2 deficiency is caused by mutations in a gene essential to the functioning of mitochondria, the energy-producing structures inside our cells. When the FARS2 gene doesn't work properly, cells can struggle to generate the energy they need, particularly in the brain, nervous system, and muscles.

Gene therapy offers a potentially transformative approach: delivering a working copy of the FARS2 gene to affected cells so they can produce the protein needed for normal mitochondrial function.

While considerable scientific and regulatory challenges remain, recent advances in genetic medicine have made this approach increasingly promising.

Our Research Strategy

We're pursuing a gene therapy program in collaboration with leading researchers at The Jackson Laboratory (JAX) and Dr. Stephen Gray, a nationally recognized gene therapy scientist at UT Southwestern Medical Center.

Our strategy focuses on three major objectives:

  • Developing a model of FARS2 deficiency. JAX is creating genetically engineered mice carrying disease-causing FARS2 mutations. These animals will allow scientists to better understand how the disease progresses and evaluate potential treatments.

  • Developing an effective gene delivery system. We're exploring advanced adeno-associated virus (AAV) technology designed to deliver a functioning FARS2 gene to cells in the nervous system. A newer delivery approach that may cross the blood-brain barrier more efficiently is a leading candidate, although its safety and effectiveness still require evaluation.

  • Testing whether gene therapy can change the course of the disease. An especially important goal is to determine whether treatment can help individuals who already have symptoms, rather than working only when administered very early in life.

The program is designed to evaluate promising technologies while maintaining alternative approaches if the leading strategy encounters obstacles.

Progress and Next Steps

Important groundwork is already underway.

JAX has made progress developing the mouse models needed to study FARS2 deficiency. These models are a critical foundation for testing whether a gene therapy can improve neurological function and slow disease progression.

Our next steps include:

  1. Establishing and characterizing the FARS2 mouse models.

  2. Selecting and developing the most promising gene delivery system.

  3. Testing whether treatment reaches the appropriate cells and produces the needed protein.

  4. Evaluating safety and effectiveness, including treatment after symptoms have developed.

  5. If the results justify it, advancing toward the manufacturing, regulatory studies, and clinical trial preparations required for testing in humans.

Our ultimate objective is to move a promising therapy into an early-stage human clinical trial. Whether that becomes possible will depend on the results of preclinical research, safety testing, regulatory review, and fundraising.

A Breakthrough With Broader Implications

FARS2 is one of thousands of rare genetic diseases for which no cure currently exists.

One of the greatest challenges in rare disease medicine is finding ways to develop treatments for very small patient populations without the enormous costs and long timelines typically associated with pharmaceutical development.

By building reusable research models, developing partnerships, and testing innovative delivery technologies, we hope our work can contribute to a more efficient path for treating other rare genetic disorders.

Our vision is bigger than one disease: to help demonstrate that even the rarest genetic conditions can become targets for life-changing treatments.